About Kanyos Bio
Kanyos Bio is a company based in Cambridge (United States) founded in 2015 was acquired by Anokion in September 2019.. Kanyos Bio has raised $16.41 million across 1 funding round from investors including Astellas Pharma, Anokion and Versant Ventures. The company has 12 employees as of December 31, 2022. Kanyos Bio offers products and services including SynCeD, ACeD-it, ACeD, and MoveS-it. Kanyos Bio operates in a competitive market with competitors including BeiGene, Biogen, Moderna, UCB and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 12 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kanyos Bio Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.41 M (USD)
in 1 rounds
-
Latest Funding Round
$16.41 M (USD), Series A
Jun 12, 2015
-
Investors
Astellas Pharma
& 4 more
-
Employee Count
12
as on Dec 31, 2022
-
Acquired by
Anokion
(Sep 11, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kanyos Bio
Kanyos Bio offers a comprehensive portfolio of products and services, including SynCeD, ACeD-it, ACeD, and MoveS-it. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for treating celiac disease through immune tolerance
Treatment targeting celiac disease with engineered antigens
Additional therapy for celiac disease management
Platform for multiple sclerosis treatment via immune modulation
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Kanyos Bio
Kanyos Bio has successfully raised a total of $16.41M through 1 strategic funding round. The most recent funding activity was a Series A round of $16.41 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $16.4M
-
First Round
First Round
(12 Jun 2015)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2015 | Amount | Series A - Kanyos Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kanyos Bio
Kanyos Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Astellas Pharma, Anokion and Versant Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kanyos Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kanyos Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kanyos Bio Comparisons
Competitors of Kanyos Bio
Kanyos Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Biogen, Moderna, UCB and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kanyos Bio
Frequently Asked Questions about Kanyos Bio
When was Kanyos Bio founded?
Kanyos Bio was founded in 2015.
Where is Kanyos Bio located?
Kanyos Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Kanyos Bio a funded company?
Kanyos Bio is a funded company, having raised a total of $16.41M across 1 funding round to date. The company's 1st funding round was a Series A of $16.41M, raised on Jun 12, 2015.
How many employees does Kanyos Bio have?
As of Dec 31, 2022, the latest employee count at Kanyos Bio is 12.
What does Kanyos Bio do?
Kanyos Bio is developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease. Their technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland. The Hubbell lab at the EPFL developed a method to harness the tolerogenic potential of the erythrocyte by engineering proteins to bind to circulating erythrocytes after simple intravenous injection. So, as the erythrocytes undergo natural cell death and are processed by immune cells, their protein cargo (the engineered proteins) are tolerized as well. As an independent affiliate, Kanyos aims to develop antigen-specific, disease-modifying therapies for patients with type-1 diabetes and celiac disease by leveraging the immunotechnology expertise of Anokion and the clinical translation experience of Astellas.
Who are the top competitors of Kanyos Bio?
Kanyos Bio's top competitors include Moderna, BeiGene and Serum Institute of India.
What products or services does Kanyos Bio offer?
Kanyos Bio offers SynCeD, ACeD-it, ACeD, and MoveS-it.
Who are Kanyos Bio's investors?
Kanyos Bio has 5 investors. Key investors include Astellas Pharma, Anokion, Versant Ventures, Novartis Venture Fund, and Novo Holdings.